Comparative Pharmacology
Head-to-head clinical analysis: SULFANILAMIDE versus SULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFANILAMIDE versus SULLA.
SULFANILAMIDE vs SULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folic acid synthesis.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
2-4 g orally initially, then 2-4 g every 4-6 hours, not to exceed 12 g/day; intravenous: 4-8 g/day in divided doses every 6-8 hours.
100 mg orally once daily, increased to 200 mg daily if needed.
None Documented
None Documented
Terminal elimination half-life: 7-12 hours; prolonged in renal impairment (up to 24-48 hours).
Clinical Note
moderateSulfanilamide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide."
Clinical Note
moderateSulfanilamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Atorvastatin."
Clinical Note
moderateSulfanilamide + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine."
Clinical Note
moderate6-12 hours; prolonged in renal impairment (up to 30 hours)
Primarily renal via glomerular filtration and tubular secretion; ~50-70% excreted unchanged in urine; biliary/fecal excretion minimal (<5%).
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
Sulfanilamide + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulfanilamide."